EVIS Bioscience AG
Developing next-generation non-viral gene delivery systems.
Gene therapy is changing the future of medicine, receiving the first FDA approval for eye disease in 2017. Adeno-associated virus (AAV) is the most efficient vector for delivering genes to the eye. However, it displays relevant drawbacks/limits that may render the treatment ineffective. EVIS Bioscience developed a next-generation non-viral vehicle for safe gene delivery into the retina. Founded by Dr Elita Montanari, Prof. Gianfranco Vento, and Tommaso Caselli, EVIS Bioscience spun out of ETH Zürich in June 2024. The company's technology enables the efficient loading of genes into natural extracellular vesicles (EVs), which may target specific tissues. With the rise of novel genetic therapies, the market for delivery technologies has surged and is projected to reach $12 billion by 2030.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
EVIS Bioscience AG
Developing next-generation non-viral gene delivery systems.
Headquarter:
Zürich ETH-Hönggerberg
Foundation Date:
June 2024
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
- Nano technologies
- Medtech
Support received
